首页> 外文期刊>Frontiers in Oncology >Prediction of Response to Preoperative Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Using Multicenter CT-Based Radiomic Analysis
【24h】

Prediction of Response to Preoperative Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Using Multicenter CT-Based Radiomic Analysis

机译:用多中心CT基辐射瘤分析预测局部晚期宫颈癌术前新辅助化疗的响应

获取原文
           

摘要

Objective: To investigate whether pre-treatment CT-derived radiomic features could be applied for prediction of clinical response to neoadjuvant chemotherapy (NACT) in locally advanced cervical cancer (LACC). Patients and Methods: Two hundred and seventy-seven LACC patients treated with NACT followed by surgery/radiotherapy were included in this multi-institution retrospective study. One thousand and ninety-four radiomic features were extracted from venous contrast enhanced and non-enhanced CT imaging for each patient. Five combined methods of feature selection were used to reduce dimension of features. Radiomics signature was constructed by Random Forest (RF) method in a primary cohort of 221 patients. A combined model incorporating radiomics signature with clinical factors was developed using multivariable logistic regression. Prediction performance was then tested in a validation cohort of 56 patients. Results: Radiomics signature containing pre- and post-contrast imaging features can adequately distinguish chemotherapeutic responders from non-responders in both primary and validation cohorts [AUCs: 0.773 (95% CI, 0.701–0.845) and 0.816 (95% CI, 0.690-0.942), respectively] and remain relatively stable across centers. The combined model has a better predictive performance with an AUC of 0.803 (95% CI, 0.734–0.872) in the primary set and an AUC of 0.821 (95% CI, 0.697–0.946) in the validation set, compared to radiomics signature alone. Both models showed good discrimination, calibration. Conclusion: Newly developed radiomic model provided an easy-to-use predictor of chemotherapeutic response with improved predictive ability, which might facilitate optimal treatment strategies tailored for individual LACC patients.
机译:目的:探讨是否可以应用预处理的CT衍生的射出物特征来预测局部晚期宫颈癌(LACC)对新辅助化疗(NACT)的临床反应。患者及方法:在这个多机构回顾性研究中,包括手术/放射治疗的两百七十七患者。从静脉对比度提高了一千九十四个射出分子,并为每位患者的静脉对比增强和非增强CT成像。使用五种特征选择方法来减少特征的维度。在221名患者的主要队列中,随机森林(RF)方法构建了辐射瘤签名。利用多变量的逻辑回归开发了一种结合着临床因素的含助聚物签名的组合模型。然后在56名患者的验证队列中进行预测性能。结果:含有预先和对比度成像特征的辐射瘤特征可以充分区分从初级和验证队列的非响应者的化学治疗响应者[AUCS:0.773(95%CI,0.701-0.845)和0.816(95%CI,0.690- 0.942)分别跨中心仍然相对稳定。组合模型在初步组中具有0.803(95%CI,0.734-0.872)的AUC的预测性能,验证集中的初级组和0.821(95%CI,0.697-0.946)的AUC,与单独的辐射瘤签名相比。两种模型都显示出良好的歧视,校准。结论:新开发的射线模型提供了一种易于使用的化学治疗反应预测因素,具有改善的预测能力,这可能促进针对个体LACC患者量身定制的最佳治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号